I'm sure they will be happy to provide you with an answer when they meet with you.
What I can tell you, however, is that we have been very sensitive and sensitized to this very important project for many years. You are absolutely right that the nature of these diseases is such that very often the pharmas are not all that interested in engaging in research because the potential markets are extremely small. It's really for us to support research in this area, which we have done. We've done it at the level of understanding what diseases are, so that we can target proper therapeutics for them. In particular, we've had a very successful collaborative initiative on rare diseases with Genome Canada, which has led, I must say, to the discovery of several new genes for rare disorders. I think there is quite a bit of hope there for patients with these disorders.
We've also been involved with the provinces in a major clinical trial for enzyme replacement therapy in Fabry disease. We are clearly aware of the problem, and we've been ramping up our research efforts in that area. We are not involved in regulating, as I'm sure you understand.
I apologize for answering your question in English. I should have answered in French, but you seem to have understood what I said.